Selank
Heptapeptide anxiolytic and nootropic (Thr‑Lys‑Pro‑Arg‑Pro‑Gly‑Pro) designed as a mild, non-sedating modulator of inhibitory tone in the central nervous system.
Explore calculators for this peptide
Use the Peptide Research Tools to experiment with intranasal microgram-range exposure models for Selank (per-spray, per-day and per-course). All values are placeholders and must be aligned with your own research protocol.
Open Selank in calculators →
Research frame & potential applications
Selank is positioned as a peptide-based anxiolytic that enhances inhibitory signalling and adjusts expression of genes related to GABA, monoamine metabolism and synaptic function.
It is studied for reducing anxiety and stress while preserving wakefulness and cognitive performance, making it attractive in “calm focus” and stress-resilience research paradigms.
Research areas & putative benefits
Where Selank typically appears in CNS and stress research designs.
- General anxiety and stress-related states, including comparisons to classical benzodiazepines.
- “Calm productivity” scenarios involving attention, information processing and cognitive performance under load.
- Models of GABA–glutamate balance and cross-talk with serotonin and dopamine systems.
- Longer-term stress-resilience and burnout-fatigue style paradigms in exploratory settings.
Mechanism stack
Proposed mechanisms behind Selank’s anxiolytic and cognitive profile.
GABA-A receptors
Positive allosteric modulation
Binding and electrophysiology studies suggest Selank enhances GABA-A receptor responsiveness as a positive allosteric modulator, without acting like a classical benzodiazepine at the same sites.
Gene expression
GABA and monoamine pathways
Transcriptomic analyses show shifts in the expression of genes involved in GABAergic transmission, neurotransmitter metabolism and synaptic regulation, indicating regulatory actions beyond acute receptor binding.
Stress response
Anxiolysis without strong sedation
Clinical observations describe reduced anxiety and improved stress tolerance with minimal sedation or cognitive dulling, consistent with modest potentiation of inhibitory tone rather than heavy CNS depression.
Delivery
Intranasal CNS access
Selank is typically administered intranasally in microgram doses to favour relatively rapid central nervous system exposure while keeping systemic dose very low.
Risk frame & unknowns
Limitations and open questions around Selank as a research tool.
Important research caveats
- Most clinical work is region-specific, with few large, multicentre, long-term trials.
- Chronic daily intranasal use and discontinuation patterns are not comprehensively mapped.
- Interactions with benzodiazepines, SSRIs, stimulants or other peptides are poorly characterised.
- Wellness and biohacking use often extrapolates beyond the conservative effects reported in controlled studies.
This dossier summarizes mechanistic, preclinical and clinical findings on Selank for scientific and educational purposes only.
It does not provide medical advice, treatment guidance or dosing recommendations.